ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1434	National Cancer Institute	Html	en	Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia.	CLL 0.563454 German CLL Study 0.551069 monoclonal B-cell lymphocytosis 0.528403 Engl J Med 0.555252 trial 0.525679 leukemia group 0.552678 M. Prolymphocytic leukemia 0.545972 Routine chronic administration 0.534661 lymphocytic leukemia patients 0.591222 Leukemia group B. 0.542105 CLL Study Group 0.54078 cyclophosphamide 0.529502 Byrd JC 0.527428 Keating MJ 0.535835 advanced chronic 0.539233 patients 0.592663 Lymphocytic Leukemia Study 0.593872 T-cell prolymphocytic leukemia 0.546745 refractory high-risk chronic 0.534243 refractory chronic 0.528565 Adult Leukemia Group 0.542021 Leuk Lymphoma 0.531402 Lymphocytic Leukemia section 0.595648 fludarabine 0.547348 alemtuzumab versus fludarabine 0.527105	untreated B chronic 0.530625 et al. 0.648755 treatment 0.535273 small lymphocytic lymphoma 0.590269 French Cooperative Group 0.528743 German Chronic Lymphocytic 0.583925 Relapsed Chronic Lymphocytic 0.579501 acute myeloid leukemia 0.53754 stem cell 0.529413 Leukemia Study Group 0.55235 rituximab 0.530116 fludarabine-refractory B-cell chronic 0.53547 CLL therapy 0.52689 chronic lymphoid leukemia 0.573599 CLL Study Group. 0.526303 Abstract 0.627578 therapy 0.53011 Clin Oncol 0.713099 hairy cell leukemia 0.553353 blood 0.56117 chronic lymphocytic leukemia 0.965039 chronic lymphocytic leukaemia 0.705583 previously untreated patients 0.578343 allogeneic stem cell 0.525551	CLICK HERE
1584	National Cancer Institute	Html	en	Anal Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of anal cancer.	cancer treatment 0.433322 diagnose anal cancer 0.423593 Anal Cancer Treatment 0.419952 metastatic anal cancer 0.412176 Frequent anal redness 0.384126 body 0.434753 PDQ cancer information 0.446236 clinical trial search 0.504831 anal cancer spreads 0.410812 clinical trials 0.887836 cancer information summary 0.419039 clinical trial 0.647154 anus 0.449257 patients 0.429875 treatment clinical trial 0.380816 NCI PDQ cancer 0.384659 malignant tumor cells 0.380765 radiation therapy 0.718553 Treatment Editorial Board 0.382929 human immunodeficiency virus 0.375987 rectum 0.3805 General information 0.426863 general cancer information 0.376766 treatment 0.612453 abdominoperineal resection 0.403255	receptive anal intercourse 0.384527 new cancer treatments 0.377037 NCI-supported cancer 0.425485 cancer cells 0.46124 Cancer Information Service 0.376813 sphincter muscles 0.384557 treatment clinical trials 0.40741 National Cancer Institute 0.461854 Recurrent anal cancer 0.435676 new treatment 0.505194 external-beam radiation therapy 0.454262 IIIA anal cancer 0.402258 IIIB anal cancer 0.401297 anal cancer 0.792189 new treatment options 0.426789 anal opening 0.376839 cancer clinical trials 0.506964 stage 0.400723 Local resection 0.453758 tumor 0.401265 comprehensive cancer information 0.375327 internal radiation therapy 0.496063 cancer 0.970468 information 0.453326	CLICK HERE
1588	National Cancer Institute	Html	en	Childhood Soft Tissue Sarcoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood soft tissue sarcomas.	Plexiform fibrohistiocytic tumor 0.280012 malignant tumor cells 0.307621 cancer treatment 0.290865 soft tissue cell 0.275637 rare tumor 0.289328 Inflammatory myofibroblastic tumor 0.282045 childhood soft tissue 0.441268 cell tumor 0.287204 body 0.349975 type 0.32132 PDQ cancer information 0.285649 children 0.277658 clinical trials 0.413146 clinical trial 0.299958 clear cell sarcoma 0.298146 Malignant triton tumor 0.279981 blood vessels 0.296075 smooth muscle tumor 0.277296 lymph nodes 0.29136 radiation therapy 0.449797 soft tissue sarcoma 0.971932 cartilage tumor 0.284625 treatment 0.443484 synovial sarcoma 0.284633	Primitive neuroectodermal tumor 0.276261 nerve sheath tumor 0.323482 chromosome switches places 0.389422 cancer cells 0.417787 tumor cells 0.415668 tumor suppressor gene 0.277153 genetic change 0.398935 soft tissue sarcomas 0.289965 /extraskeletal Ewing tumor 0.27615 fibrous tissue tumor 0.342556 tissue sarcoma cells 0.300511 primary tumor 0.287542 metastatic tumor 0.275814 following types 0.304501 soft tissue tumors 0.283665 PDQ summary 0.323186 tumors 0.289287 tumor 0.552574 Tissue Sarcoma Treatment 0.342732 certain genetic change 0.378247 cancer 0.496155 information 0.290056 Adult Soft Tissue 0.29745 fast-growing tumor 0.287416	CLICK HERE
1642	National Cancer Institute	Html	en	714-X (PDQ®)–Patient Version	714-X is made by mixing chemicals with camphor, a natural substance that comes from the wood and bark of the camphor tree. Read about the theory behind using 714-X and its current use in cancer patients.	peer-reviewed scientific journals 0.537641 treatment 0.534968 cancer treatment 0.501509 cancer prevention 0.385702 Information Service 1-800-4-CANCER 0.351897 Complementary Therapies Editorial 0.514523 United States 0.392202 Cancer Information Specialist 0.412867 Drug Administration 0.382831 NCI Best Case 0.355021 Cancer Information Service 0.561203 PDQ cancer information 0.744788 Cancer Complementary 0.449411 CAM therapies 0.422313 treatment clinical trials 0.37249 National Cancer Institute 0.876336 clinical trials 0.717035 alternative medicine 0.550954 health care 0.367057 scientific journals 0.644656 cancer information summary 0.608674 alternative cancer therapies 0.435258 Federal Trade Commission 0.400026 National Institutes 0.384082	clinical trial 0.420566 National Center 0.380596 CAM cancer research 0.409541 new treatment 0.361031 breast cancer prevention 0.380639 PDQ 714-X 0.397489 PDQ summaries 0.352729 cancer patients 0.471011 Cancer Care page 0.383195 latest published information 0.365664 NCI’s PDQ 0.390788 PDQ summary 0.383221 Integrative Health 0.378723 NCI PDQ cancer 0.513504 cancer information database 0.431786 alternative therapies 0.488998 cancer information summaries 0.432385 Therapies Editorial Board 0.457631 cancer 0.995087 research studies 0.395284 714-X 0.480793 fight cancer cells 0.39917 PDQ Integrative 0.349747	CLICK HERE
1756	National Cancer Institute	Html	en	Alcohol and Cancer Risk	A fact sheet that summarizes the evidence linking alcohol consumption to the risk of various cancers. Includes information about factors that affect the risk of alcohol-associated cancers.	major risk factor 0.235988 esophageal cancer 0.270931 alcohol content 0.304765 alcohol-associated cancer risk 0.218724 alcohol dehydrogenase 0.277499 Heavy alcohol 0.291007 alcohol consumption 0.743494 modestly increased risk 0.222903 colorectal cancer risk 0.261495 alcohol drinkers 0.284781 drinking alcohol 0.321106 alcohol intake 0.325944 ethyl alcohol 0.305684 percent alcohol 0.349039 moderate alcohol drinking 0.333262 Alcohol Abuse 0.303318 studies 0.234236 cancer risk declines 0.219417 alcohol 0.928418 pure alcohol 0.321046	Moderate alcohol intake 0.283695 esophageal squamous cell 0.212278 breast cancer risk 0.237174 S. Alcohol drinking 0.301428 alcohol-related esophageal cancer 0.211228 breast cancer 0.381145 alcohol drinking 0.503002 neck cancers 0.250896 pancreatic cancer risk 0.215956 neck cancer 0.200912 regular alcohol consumption 0.359735 et al 0.397799 cancer risk 0.361737 cancers 0.264383 oral cavity 0.23106 cancer 0.549181 risk 0.431925 liver cancer 0.219113 enzyme drink alcohol 0.313977	CLICK HERE
1909	National Cancer Institute	Html	es	Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica.	siguientes procedimientos 0.425256 células madre 0.845072 Chronic Myelogenous Leukemia 0.438357 leucemia linfoblástica aguda 0.438362 hueso compacto 0.417479 enlace drugs approved 0.436902 cromosoma filadelfia 0.526385 célula madre mieloide 0.437781 Sudores nocturnos 0.404959 células anormales.ampliar aspiración 0.417986 enlace medicamentos 0.404489 National Cancer Institute 0.403419 siguientes riesgos 0.40277	Instituto Nacional 0.405884 célula madre linfoide 0.438967 PDQ Tratamiento 0.410126 hijos.ampliar cromosoma filadelfia 0.412419 leucemia mielógena 0.99599 Physician Data Query 0.412686 laboratorio piezas 0.403757 leucemia mieloide aguda 0.437955 siguientes exámenes 0.405471 célula madre 0.512002 células sanguíneas maduras 0.448469 ósea elabora células 0.429135 siguientes sumarios 0.40998	CLICK HERE
2011	National Cancer Institute	Html	es	Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón.	lung cancer screening 0.491865 Berg CD 0.308884 UK Lung Cancer 0.309828 Cooperative Early Lung 0.306877 Lung Cancer Study 0.310626 lung cancer 0.996403 Reduced lung-cancer mortality 0.308509 American Cancer Society 0.314872 Sloan-Kettering Lung Study 0.306329 Extended lung 0.305748 lung-cancer screening 0.305282 Lung Screening Trial 0.34779 Preventive Services Task 0.315666 early lung cancer 0.370281 Cancer Res 0.308506 screening results 0.305543 exámenes detección 0.3124 Screening Trial 0.41076 lung-cancer mortality with 0.308638 Randomized Danish Lung 0.306065 CT screening 0.322848 Natl Cancer Inst 0.348878 small lung 0.309116 Lung Cancer Risk 0.310447 from baseline screening 0.305357	More lung 0.305626 Screening Trial with 0.311542 early stage lung 0.306471 Is curable lung 0.306471 cytologic screening 0.312546 Hocking WG 0.305973 Hopkins Lung Project 0.306129 CT screening according 0.305575 Danish Lung Cancer 0.338861 Lung Cancer Action 0.32014 randomised danish lung 0.306155 National Lung Screening 0.345051 Intern Med 0.314222 lung cancer detection 0.362796 Services Task Force 0.31539 Randomized Lung Cancer 0.310797 from semi-annual screening 0.30542 PLCO Cancer Screening 0.310194 Mayo Lung Project 0.341943 lung cancers detected 0.306094 Memorial Sloan-Kettering 0.306282 Cancer Action Project 0.310925 Lung Project revisited 0.306785 Cancer Screening Trial 0.390805	CLICK HERE
15639	National Cancer Institute	Html	null	Grants	Learn about the different grants that are available, such as Research Projects Grants, SPORE Grants, career awards and cancer education grants, training grants, and others.			CLICK HERE
16473	National Cancer Institute	Html	en	Nivolumab Improves Survival for Patients with Recurrent Head and Neck Cancer	A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.	platinum-based chemotherapy 0.436007 immune checkpoint inhibitor 0.707571 pembrolizumab block 0.240544 checkpoint inhibitor nivolumab 0.489462 standard therapy group 0.856853 HNSCC tumor growth 0.401684 squamous cells 0.272124 Cancer Therapy Evaluation 0.372634 overall survival 0.94063 broader group 0.255871 poor prognoses 0.250488 median progression-free survival 0.452131 Pittsburgh Medical Center 0.399432 Maura L. Gillison 0.401307 Bristol-Myers Squibb 0.274378 median overall survival 0.493854 patients 0.514717 metastatic HNSCC 0.274208 HNSCC 0.412159 effective second-line therapy 0.394916 Shakun Malik 0.250672 Drug Administration 0.252661 cancer cells 0.262643 treatment-related adverse events 0.35048	Human papillomavirus 0.256631 better treatment 0.263098 unacceptable side effects 0.245803 median follow-up 0.28334 PD-L1—a molecule 0.240638 nivolumab group 0.622355 tumor cells 0.248287 new trial 0.243059 standard chemotherapy 0.417786 Ohio State University 0.396086 median length 0.283635 immune cells 0.271394 salivary glands 0.258435 nasal passages 0.247938 Robert L. Ferris 0.397098 Cancer Institute 0.278018 neck cancer 0.259993 tumor response 0.240293 common adverse events 0.34039 New England Journal 0.393835 oral cavity 0.246829 checkpoint molecule PD-1 0.389662 Earlier studies 0.247274 phase III trial 0.261728	CLICK HERE
16842	National Cancer Institute	Html	en	Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research	The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here.	predoctoral fellows 0.736483 cancer nanobiotechnology 0.632531 optimal treatment 0.545276 Johns Hopkins University 0.729715 journal club 0.539106 novel cancer diagnostics 0.713403 program fosters 0.562779 steady state number 0.670018 epigenetic markers 0.560601 tumor boards 0.538166 NTCR program 0.576419 new frontier 0.564875 individual patient 0.643505 engineering/physics discipline 0.563571 physical sciences-oncology center 0.676488 lab course 0.540911 new modalities 0.563 cellular / cancer 0.59221 Johns Hopkins Institute 0.669855 dedicated annual symposium 0.651728 experimental facilities 0.538368 Vivo Cellular 0.548936 Molecular Imaging Center 0.688968 black-box input-output techniques 0.710638	scientific exploration 0.554225 clinical resources 0.5443 human diseases 0.555299 cancer cell functions 0.720912 clinical conferences 0.540551 high-throughput diagnostic tools 0.682779 non-viral delivery systems 0.686087 unique educational resources 0.657197 postdoctoral fellows 0.715577 Principal Investigator 0.564913 therapeutic tools 0.551025 Pancreatic Cancer Center 0.731915 Ludwick Center 0.581555 NTCR trainees 0.59515 cancer nanotechnology excellence 0.742492 outstanding trainees 0.578764 disease phenotype 0.55677 Comprehensive Cancer Center 0.727928 Cancer Genetics 0.585039 NTCR fellows 0.742981 engineer novel drug/antibody/siRNA 0.668859 human cancers 0.551276 core courses 0.541397 Training Focus 0.565904	CLICK HERE